Eighteen-year results of treatment of uveal melanoma using Ruthenium-106 + Rhodium-106 brachytherapy
https://doi.org/10.29235/1814-6023-2021-18-3-284-291
Abstract
The objective of the study was to evaluate the results of Ruthenium-106 (106Ru) + Rhodium-106 (106Rh) brachytherapy in uveal melanoma (UM) patients.
The data for the period 2001–2018 were taken from the Belarusian Cancer Registry and medical records of patients with clinically diagnosed uveal melanoma who received treatment at the N. N. Alexandrov National Cancer Centre of Belarus. A total of 383 patients were included in the study. 106Ru + 106Rh β-ophthalmic applicators were used for brachytherapy (BT). The calculated dose to the tumor apex was 120–130 Gy, while the reduced 100–110 Gy was administered to tumors close to the optic nerve. To analyze the treatment outcomes, patients were divided into three groups based on a basal diameter of a tumor.
Out of a total 383 patients, complete tumor resolution was observed in 282 (73.6 %), tumor stabilization was present in 76 (19.8 %). Continued tumor growth and tumor relapse were observed in 34 (9.13 %) and 50 (13.05 %) patients, respectively. 59 (15.1 %) patients underwent enucleation. The metastatic disease developed in 47 (12.3 %) cases. BT adverse effects were observed in 21.3 % cases. The relapse-free survival in the group of patients with a basal tumor diameter of up to 9 mm was 76.0 ± 6.3 %, which was higher than that in the groups with a large basal diameter (p = 0.002). Over a 15-year follow-up period, almost half of the patients (52.2 ± 15.6 %) with a tumor base of more than 12 mm relapsed.
Considering the high rates of the continued tumor growth during treatment in patients with a basal tumor diameter of more than 12 mm, combined therapy must be used in this group.
About the Authors
L. V. Naumenko
N. N. Alexandrov National Cancer Centre of Belarus
Belarus
Belarus
Larisa V. Naumenko – Ph. D. (Med.), Leading Researcher.
223040, Lesnoy, Minsk region
K. P. Zhyliayeva
N. N. Alexandrov National Cancer Centre of Belarus
Belarus
Belarus
Katsiaryna P. Zhyliayeva – ophthalmologist
223040, Lesnoy, Minsk region
A. A. Evmenenko
N. N. Alexandrov National Cancer Centre of Belarus
Belarus
Belarus
Alesia A. Evmenenko – Ph. D. (Biol.)
223040, Lesnoy, Minsk region
I. Yu. Zherka
N. N. Alexandrov National Cancer Centre of Belarus
Belarus
Belarus
Iryna Yu. Zherka – ophthalmologist
223040, Lesnoy, Minsk region
S. A. Krasny
N. N. Alexandrov National Cancer Centre of Belarus
Belarus
Belarus
Siarhei A. Krasny – Corresponding Member, D. Sc. (Med.), Professor
223040, Lesnoy, Minsk region
References
1. Ziangirova G. G., Likhvantseva V. G. Tumors of the vascular tract of the eye. Moscow, Poslednee slovo Publ., 2003, 454 p. (in Russian).
2. Virgili G., Gatta G., Ciccolallo L., Capocaccia R., Biggeri A., Crocetti E., Lutz J.-M., Paci E. Incidence of uveal melanoma in Europe. Ophthalmology, 2007, vol. 114, no. 12, рр. 2309‒2315e2. https://doi.org/10.1016/j.ophtha.2007.01.032
3. Naumenko L. V., Zhilyaeva E. P., Evmenenko A. A. Analysis of statistical indicators of uveal melanoma prevalence in the Republic of Belarus over the period 1997‒2016. Onkologicheskii zhurnal [Oncological journal], 2018, vol. 12, no. 3, рр. 21–28 (in Russian).
4. Margo C. E. The collaborative ocular melanoma study: an overview. Cancer Control, 2004, vol. 11, no. 5, рр. 304‒309. https://doi.org/10.1177/107327480401100504
5. Brovkina A. F., Khionidi Ya. N. Late complications of brachytherapy for choroidal melanomas and possibility of their prevention. Vestnik oftal’mologii [Bulletin of ophthalmology], 2018, vol. 134, no. 1, рр. 4–11 (in Russian).
6. Naumenko L. V., Zalutskii I. V. Brachytherapy with 106Ru+106Rh β-ophthalmic applicators for choroidal melanoma Т1- 2NOM0: practice guidelines No 035-0406 approved by the Ministry of Public Healthcare of the Republic of Belarus, October 23, 2016. Minsk, 2006. 18 p. (in Russian).
7. Pagliara M. M., Tagliaferri L., Azario L., Lenkowicz J., Lanza A., Autorino R., Caputo C. G., Gambacorta M. A., Valentini V., Blasi M. A. Ruthenium brachytherapy for uveal melanomas: factors affecting the development of radiation complications. Brachytherapy, 2018, vol. 17, no. 2, рр. 432–438. https://doi.org/10.1016/j.brachy.2017.11.004
8. Rice J. C., Stannard C., Cook C., Lecuona K., Myer L., Scholtz R. P. Brachytherapy and endoresection for choroidal melanoma: a cohort study. British Journal of Ophthalmology, 2014, vol. 98, no. 1, рр. 86‒91. https://doi.org/10.1136/bjophthalmol-2013-304006
9. Le B. H. A., Kim J. W., Deng H., Rayess N., Jennelle R. L., Zhou S. Y., Astrahan M. A., Berry J. L. Outcomes of choroidal melanomas treated with eye physics plaques: a 25-year review. Brachytherapy, 2018, vol. 17, no. 6, рр. 981‒989. https://doi.org/10.1016/j.brachy.2018.07.002
10. Mishra K., Quivey J., Daftari I., Weinberg V., Cole T. B., Patel K., Castro J. R., Phillips T. L., Char D. H. Long-term results of the UCSF-LBNL Randomized Trial: charged particle with helium ion versus iodine-125 plaque therapy for choroidal and ciliary body melanoma. International Journal of Radiation Oncology, Biology, Physics, 2015, vol. 92, no. 2, рр. 376–783. https://doi.org/10.1016/j.ijrobp.2015.01.029
11. Marinkovic M., Horeweg N., Fiocco M., Peters F. P., Sommers L. W., Laman M. S., Bleeker J. C., Ketelaars M., Luyten G. P. M., Creutzberg C. L. Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome. European Journal of Cancer, 2016, vol. 68, рр. 106‒113. https://doi.org/10.1016/j.ejca.2016.09.009
12. Semenova E., Finger P. T. Palladium-103 plaque radiation therapy for American Joint Committee on cancer T3- and T4-staged choroidal melanomas. JAMA Ophthalmology, 2014, vol. 132, no. 2, рр. 205‒213. https://doi.org/10.1001/jamaophthalmol.2013.5677
13. Caminal J., Padrón-Pérez N., Arias L., Masuet-Aumatell C., Gutiérrez C., Piulats J. M., Pera J., Català J., Rubio M. J., Arruga J. Transscleral resection without hypotensive anaesthesia vs iodine-125 plaque brachytherapy in the treatment of choroidal melanoma. Eye, 2016, vol. 30, no. 6, pp. 833–842. https://doi.org/10.1038/eye.2016.49
14. Chia S., Smith H., Hammer H., Kemp E. G. Incidence and indications for pars plana vitrectomy following the treatment of posterior uveal melanomas in Scotland. Eye, 2015, vol. 29, no. 6, pp. 748–756. https://doi.org/10.1038/eye.2015.20
15. Wisely C. E., Hadziahmetovic M., Reem R. E., Hade E. M., Nag S., Davidorf F. H., Martin D., Cebulla C. M. Longterm visual acuity outcomes in patients with uveal melanoma treated with 125I episcleral OSU-Nag plaque brachytherapy. Brachytherapy, 2016, vol. 15, no. 1, рр. 12‒22. https://doi.org/10.1016/j.brachy.2015.09.013
16. Stålhammar G., See T. R., Filì M., Seregard S. No gender differences in long-term survival after brachytherapy of 1,541 patients with uveal melanoma. Ocular Oncology and Pathology, 2019, vol. 5, no. 6, рр. 432‒439. https://doi.org/10.1159/000497186
Review
For citations:
Naumenko L.V., Zhyliayeva K.P., Evmenenko A.A., Zherka I.Yu., Krasny S.A. Eighteen-year results of treatment of uveal melanoma using Ruthenium-106 + Rhodium-106 brachytherapy. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2021;18(3):284-291. https://doi.org/10.29235/1814-6023-2021-18-3-284-291
Views: 979
Email this article 